ARPA-H Launches Two New Programs
EMBODY: Engineering of Immune Cells Inside the Body
The goal of EMBODY is to radically alter how immune therapies are developed and delivered for life-threatening and chronic conditions by retraining healthy immune cells, and eliminating time, cost and access hurdles.
“By developing agents that target specific immune cell types, essentially providing instructions to cells already active inside your body, we hope to make advanced immunotherapies available close to home for Americans across the country,” said EMBODY Program Manager Daria Fedyukina, Ph.D., in ARPA-H’s recent program announcement.
PRINT (Personalized Regenerative Immunocompetent Nanotechnology Tissue)
PRINT intends to use state-of-the-art bioprinting technology and a regenerative medicine approach to 3D print personalized, on organs that will not require immunosuppressive drugs.
“By starting from multiple different types of cells, we will be creating organs that will be individually matched,” said PRINT Program Manager Ryan Spitler, Ph.D., in ARPA-H’s recent program announcement. “The body will not recognize it as a foreign entity, eliminating the need of immunosuppressive drugs, which has never been done in the history of organ transplantation.”
To learn more about both programs, including how to register for the upcoming Proposers’ Days, visit the EMBODY program page and PRINT program page
- Study Supports Long-Term Prophylaxis for Hereditary Angioedema – MedCentral
Dr. Tachdjian presented his team's findings at the American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress this … - Focus on the gut-liver axis – The Hippocratic Post
… Immunology), has now investigated the effect of NorUDCA on the intestinal immune system. It was shown that NorUDCA not only inhibits pro … - NTx Establishes Scientific Advisory Board with Distinguished Leaders in Oncology
… immunology joining as inaugural members. The SAB will provide technical insight and guidance on scientific matters as NTx continues to advance its … - British Society for Immunology response to rising measles cases in the European Region
In response, the BSI has released the following statement: Dr Doug Brown, Chief Executive of the British Society for Immunology, said: “It is … - Harbour BioMed launches Élancé Therapeutics to advance next-generation obesity therapies
… immunology and oncology, announced the launch of Élancé Therapeutics (Élancé). Harnessing Harbour BioMed's proprietary HCAb-based bispecific …